Samira Sakhia - Knight Therapeutics President, Chief Financial Officer, Director
| GUD Stock | CAD 6.18 0.09 1.44% |
President
Ms. Samira Sakhia, CPA, is President, Chief Financial Officer, Director of the Company. Ms. Sakhia joined Knight as President in August 2016 and assumed the additional responsibility of Chief Financial Officer in October 2017. At Knight., Ms. Sakhia oversees the finance, business development, commercial and scientific affairs teams. Prior to joining Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing inlicensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several MA and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo for 3.2 billion. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant since 2020.
| Age | 49 |
| Tenure | 5 years |
| Address | 3400 de Maisonneuve Blvd. W., Montreal, QC, Canada, H3Z 3B8 |
| Phone | 514-484-4483 |
| Web | https://www.knighttx.com |
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Chris Gittens | Element Fleet Management | N/A | |
| Jon Younce | Stella Jones | N/A | |
| David Madrigal | Element Fleet Management | N/A | |
| Michael Sylvester | Stella Jones | N/A | |
| Timothy Johnson | Winpak | N/A | |
| Michael Opdahl | ECN Capital Corp | N/A | |
| Silvana Travaglini | Stella Jones | 52 | |
| Guy Grenier | Richelieu Hardware | N/A | |
| Eric Vachon | Stella Jones | 51 | |
| Larry Warelis | Winpak | N/A | |
| Lance Hull | ECN Capital Corp | N/A | |
| Craig Ratchford | Richelieu Hardware | N/A | |
| Gordon Murray | Stella Jones | N/A | |
| Kevin Comerford | Stella Jones | N/A | |
| David Stacey | Winpak | N/A | |
| Vito Culmone | Element Fleet Management | 54 | |
| Andre Daigle | Stella Jones | N/A | |
| Jim Raines | Stella Jones | N/A | |
| Jacqui McGillivray | Element Fleet Management | N/A | |
| Vineet Gupta | Element Fleet Management | N/A | |
| Donnie Cole | ECN Capital Corp | N/A | |
Knight Therapeutics Leadership Team
Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Ex Chairman | ||
| Monica Percario, Global Affairs | ||
| Jonathan Goodman, Chief Executive Officer, Director | ||
| Robert Lande, Independent Director | ||
| Samira Sakhia, President, Chief Financial Officer, Director | ||
| BA LLB, Executive Chairman | ||
| Michael Tremblay, Independent Director | ||
| Susan Emblem, Global Resources | ||
| Nancy Harrison, Independent Director | ||
| Sylvie Tendler, Independent Director | ||
| Stephani Saverio, Vice Development | ||
| Meir Jakobsohn, Director | ||
| Henrique Dias, Global Marketing | ||
| Jeff Martens, Global Commercial | ||
| James Gale, Independent Chairman of the Board | ||
| Arvind Utchanah, Chief Financial Officer | ||
| Leopoldo Bosano, VicePresident Operations | ||
| Jody Engel, Senior Director - Business Development | ||
| Amal Khouri, Vice President - Business Development | ||
| Janice Murray, Independent Director | ||
| Nicolas Sujoy, Independent Director | ||
| Daniela Marino, Global Compliance | ||
| Melanie Groleau, Global Clinical |
Knight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 133.90 X | ||||
| Revenue | 328.2 M | ||||
| EBITDA | 56.82 M | ||||
| Net Income | (16.84 M) | ||||
| Cash And Equivalents | 302 K | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 69.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.53 X |
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Knight Stock
Moving against Knight Stock
| 0.65 | BBD-B | Bombardier | PairCorr |
| 0.62 | ONEX | Onex Corp | PairCorr |
| 0.43 | MGA | Mega Uranium | PairCorr |
| 0.31 | CVE | Cenovus Energy | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.